JPH10509740A5 - - Google Patents

Info

Publication number
JPH10509740A5
JPH10509740A5 JP1997508693A JP50869397A JPH10509740A5 JP H10509740 A5 JPH10509740 A5 JP H10509740A5 JP 1997508693 A JP1997508693 A JP 1997508693A JP 50869397 A JP50869397 A JP 50869397A JP H10509740 A5 JPH10509740 A5 JP H10509740A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP1997508693A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10509740A (ja
Filing date
Publication date
Priority claimed from US08/693,831 external-priority patent/US6017700A/en
Application filed filed Critical
Publication of JPH10509740A publication Critical patent/JPH10509740A/ja
Publication of JPH10509740A5 publication Critical patent/JPH10509740A5/ja
Expired - Lifetime legal-status Critical Current

Links

JP9508693A 1995-08-04 1996-08-01 カチオン性オリゴヌクレオチド、ならびに関連の合成および使用の方法 Expired - Lifetime JPH10509740A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US190195P 1995-08-04 1995-08-04
US08/693,831 1996-07-31
US08/693,831 US6017700A (en) 1995-08-04 1996-07-31 Cationic oligonucleotides, and related methods of synthesis and use
US60/001,901 1996-07-31
PCT/US1996/013056 WO1997006183A1 (en) 1995-08-04 1996-08-01 Cationic oligonucleotides, and related methods of synthesis and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007208670A Division JP2008013571A (ja) 1995-08-04 2007-08-09 カチオン性オリゴヌクレオチド、ならびに関連の合成および使用の方法

Publications (2)

Publication Number Publication Date
JPH10509740A JPH10509740A (ja) 1998-09-22
JPH10509740A5 true JPH10509740A5 (enExample) 2004-09-09

Family

ID=26669648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9508693A Expired - Lifetime JPH10509740A (ja) 1995-08-04 1996-08-01 カチオン性オリゴヌクレオチド、ならびに関連の合成および使用の方法
JP2007208670A Pending JP2008013571A (ja) 1995-08-04 2007-08-09 カチオン性オリゴヌクレオチド、ならびに関連の合成および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007208670A Pending JP2008013571A (ja) 1995-08-04 2007-08-09 カチオン性オリゴヌクレオチド、ならびに関連の合成および使用の方法

Country Status (6)

Country Link
US (1) US6017700A (enExample)
EP (1) EP0785942A1 (enExample)
JP (2) JPH10509740A (enExample)
AU (1) AU702309B2 (enExample)
CA (1) CA2201963A1 (enExample)
WO (1) WO1997006183A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3090102A (en) * 2000-12-14 2002-06-24 Gen Probe Inc Method and kit for enhancing the association rates of polynucleotides
CA2494571C (en) * 2003-12-02 2010-02-09 F.Hoffmann-La Roche Ag Oligonucleotides containing molecular rods
WO2008008476A2 (en) * 2006-07-12 2008-01-17 The Regents Of The University Of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP3348564A1 (en) * 2011-05-10 2018-07-18 Bonac Corporation Process for preparing phosphate compound bearing isotope
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2880869A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
KR102285326B1 (ko) 2013-06-28 2021-08-04 에트리스 게엠베하 Rna를 세포에 도입하기 위한 조성물
US9410172B2 (en) 2013-09-16 2016-08-09 General Electric Company Isothermal amplification using oligocation-conjugated primer sequences
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
US20170056526A1 (en) 2014-02-26 2017-03-02 Ethris Gmbh Compositions for gastrointestinal administration of rna
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
KR20190058477A (ko) 2016-08-17 2019-05-29 솔스티스 바이올로직스, 리미티드 폴리뉴클레오티드 구축물
AU2018252193B2 (en) 2017-04-14 2024-12-12 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
BR112020021037A2 (pt) 2018-04-25 2021-01-19 Ethris Gmbh Composição, composição sólida, processo para a preparação de uma composição, método para preservar uma formulação de nano ou micropartícula de um agente terapeuticamente ativo, uso de um composto selecionado de alcanos c3-c5 substituídos com um ou dois grupos hidróxi, e, dispositivo
EP4297722A1 (en) 2021-02-26 2024-01-03 Ethris GmbH Formulations for aerosol formation and aerosols for the delivery of nucleic acid
JPWO2022230990A1 (enExample) * 2021-04-28 2022-11-03
JP2025529925A (ja) 2022-08-26 2025-09-09 エスリス ゲーエムベーハー 安定な脂質またはリピドイドナノ粒子懸濁液
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2025045767A1 (en) 2023-08-25 2025-03-06 Ethris Gmbh Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586704B1 (fr) * 1985-09-04 1987-12-18 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation et a un groupe chimique activable, leur synthese et leurs applications a titre de nucleases artificielles specifiques de sequences. centre national de la recherche scientifique (cnrs)
US4868105A (en) * 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
DE3916871A1 (de) * 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
AU3144593A (en) * 1991-11-25 1993-06-28 Pharmagenics, Inc. Oligonucleotides having aminohydrocarbon phosphonate moieties

Similar Documents

Publication Publication Date Title
JP2000500228A5 (enExample)
JP2000500033A5 (enExample)
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500407A5 (enExample)
JP2000500397A5 (enExample)
JP2000500125A5 (enExample)
JP2000500346A5 (enExample)
JP2000500044A5 (enExample)
JP2000500090A5 (enExample)
JP2000500257A5 (enExample)
JP2000500429A5 (enExample)